• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

MS drug trial. Repurposing drugs already in use for other diseases.

Snowdrop

Rebel without a biscuit
Messages
2,933
The MS-Smart trial will test the safety and effectiveness of three drugs used in other conditions:

  • Amiloride - licensed to treat heart disease
  • Fluoxetine - used in depression
  • Riluzole - for Motor Neurone Disease
They were identified after a review of previously published research into drugs that appear to protect the nerves from damage.

From BBC news clip at: http://www.bbc.com/news/health-32136208

The trial: http://www.ms-smart.org/
 

anciendaze

Senior Member
Messages
1,841
Please note that "drugs that appear to protect the nerves from damage" may well act against undetected infectious agents. I have previously noted that fluoxetine strongly inhibits Coxsackie B virus. This now appears to extend to a wider class of enteroviruses. (This is probably also true for a range of SSRIs. It is still too early to say if SNRIs have effects on viruses.)

While amiloride is approved for use in heart disease, particularly when there is hypertension, as a potassium-sparing diuretic it may well have off-label use in channelopathies exacerbated by hypokalemia. It may also be useful in hypomagnesemia. It has repeatedly been used to treat polyuria in patients on lithium salts. Does it have an effect on infectious agents? I don't know, but I do know that lithium levels do affect viral loads of HIV. Other electrolytes may also have effects on viral replication. Many bacteria are sensitive to potassium levels. To what extent this effect in humans is due to direct activity of ions on bacteria or to inflammatory response remains to be seen.

Exactly how riluzole extends survival by months in ALS is not clear. It is known to block specific kinds of sodium channels, as well as receptors to kainate and NMDA. Exactly what it does to glutamate receptors remains controversial.

Please note that all these drugs act on receptors for either neurotransmitters or electrolytes. These receptors have effects on many immune cells, and some directly affect either bacteria or immune response to them. These drugs all show up in psychopharmacology literature, which suggests to me that undiagnosed neurological disease may well be behind common psychiatric illnesses.